Go back to Newsroom

Psychedelic Therapy Faces Regulatory Hurdles Despite Promising Research

Key Insights

Go back to Newsroom

Go back to Newsroom

A CRO Should be the Partner that Gives Full Visibility on a Gene Therapy Trials Path

Go back to Newsroom

Go back to Newsroom

Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD

Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.

Download Go back to Newsroom

Go back to Newsroom

SCOPE Summit 2025: Emmes' Peter Ronco on Small Biopharma & Clinical Trial Partnerships

Go back to Newsroom

Go back to Newsroom

Large Language Models and Beyond: AI’s Impact on Clinical Trial Efficiency and Integrity

Go back to Newsroom

Go back to Newsroom

SCOPE Summit 2025: Peter Ronco on the Risks Small Biopharma Companies Face in Clinical Trial Partnerships

Go back to Newsroom

Go back to Newsroom

SCOPE Summit 2025: Peter Ronco Offers Tips to Small Biopharma Companies on Properly Scaling Clinical Programs

Go back to Newsroom

Go back to Newsroom

Emmes Group Earns ISO 27001:2022 Certification for Data Security

Emmes Group, a specialized, technology-enabled Contract Research Organization (CRO), has achieved ISO/IEC 27001:2022 certification after a rigorous audit. This data security certificate, widely regarded as the gold standard for Information Security Management Systems (ISMS), guarantees that Emmes Group and its subsidiary companies, Emmes and Veridix, adhere to the highest global standards for safeguarding sensitive information across its workforce, processes, and technology.

Download Go back to Newsroom

Go back to Newsroom

Trust on Trial: Why Vaccine Volunteers Are Saying ‘No’ in Discover Pharma

Go back to Newsroom

Go back to Newsroom

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Phase 1 Launch of New eSource Technology Marks OptymEdge’s Evolution Into a Full-Service Ophthalmic Research Partner 

Go back to Newsroom